Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-13-3490 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-13-3490 C4268342!4268342!24947931     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2014 ; 20 (24): 6314-23 Nephropedia Template TP {{tp|p=24947931|t=2014. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors |pdf=|usr=}}{{24947931}} gab.com Text Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24947931 #FOAvip Purpose: To examine the utility and reliability of obtaining early echocardiographic measurements of left ventricular (LV) remodeling as well as blood biomarkers of cardiac injury in asymptomatic childhood cancer survivors at risk for LV dysfunction and congestive heart failure due to past exposure to anthracycline chemotherapy. Experimental Design: Using a cross-sectional design, anthracycline-exposed childhood cancer survivors with preserved EF (?50%) were evaluated using early echocardiographic indices and blood biomarkers of LV dysfunction. Survivors treated with ?300mg/m2 anthracyclines (high-risk [HR]: n=100) were compared with: i) those treated with <300 mg/m2 anthracyclines (low-risk [LR]: n=50) and matched healthy controls (HC: n=50). All echocardiograms were interpreted by an institutional cardiologist and a study cardiologist blinded to risk status. Results: Time from diagnosis was comparable for HR (12.0y) and LR (13.2y, p=0.8) survivors. Echocardiograms: HR had lower LV thickness-dimension ratio (Z-score: HR: ?0.62, LR: ?0.03, HC: ?0.02; p<0.001), increased LV wall stress (HR: 66.7 g/cm2, LR: 56.6 g/cm2, HC: 54.2 g/cm2; p<0.01) and higher myocardial performance index (HR: 0.51, LR: 0.46, HC: 0.46; P<0.01). Inter-observer correlation (clinical/blinded reading) for all echocardiographic indices was excellent (range: R=0.76-0.97, p<0.001). Blood biomarkers: With the exception of NT-proBNP (r=0.28, p<0.01), there was no correlation between blood biomarkers (BNP, Troponin-T, ST-2, Galectin-3) and LV dysfunction. Conclusion: Childhood cancer survivors with preserved EF 10+years from anthracycline exposure had dose-dependent changes in echocardiographic markers of LV dysfunction. Twit Text FOAVip Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24947931 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24947931 #FOAvip English Wikipedia <ref>{{Cite pmid|24947931}}</ref> Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors #MMPMID24947931 Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; WilsonM KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S Clin Cancer Res 2014[Dec]; 20 (24): 6314-23 PMID24947931show ga Purpose: To examine the utility and reliability of obtaining early echocardiographic measurements of left ventricular (LV) remodeling as well as blood biomarkers of cardiac injury in asymptomatic childhood cancer survivors at risk for LV dysfunction and congestive heart failure due to past exposure to anthracycline chemotherapy. Experimental Design: Using a cross-sectional design, anthracycline-exposed childhood cancer survivors with preserved EF (?50%) were evaluated using early echocardiographic indices and blood biomarkers of LV dysfunction. Survivors treated with ?300mg/m2 anthracyclines (high-risk [HR]: n=100) were compared with: i) those treated with <300 mg/m2 anthracyclines (low-risk [LR]: n=50) and matched healthy controls (HC: n=50). All echocardiograms were interpreted by an institutional cardiologist and a study cardiologist blinded to risk status. Results: Time from diagnosis was comparable for HR (12.0y) and LR (13.2y, p=0.8) survivors. Echocardiograms: HR had lower LV thickness-dimension ratio (Z-score: HR: ?0.62, LR: ?0.03, HC: ?0.02; p<0.001), increased LV wall stress (HR: 66.7 g/cm2, LR: 56.6 g/cm2, HC: 54.2 g/cm2; p<0.01) and higher myocardial performance index (HR: 0.51, LR: 0.46, HC: 0.46; P<0.01). Inter-observer correlation (clinical/blinded reading) for all echocardiographic indices was excellent (range: R=0.76-0.97, p<0.001). Blood biomarkers: With the exception of NT-proBNP (r=0.28, p<0.01), there was no correlation between blood biomarkers (BNP, Troponin-T, ST-2, Galectin-3) and LV dysfunction. Conclusion: Childhood cancer survivors with preserved EF 10+years from anthracycline exposure had dose-dependent changes in echocardiographic markers of LV dysfunction. äScreening for cardiac dysfunction in anthracycline-exposed childhood c(epmc).pdf DeepDyve Pubget Overpricing